Tissue Expression of Androgen Receptor Splice Variant 7 at Radical Prostatectomy Predicts Risk of Progression in Untreated Nonmetastatic Prostate Cancer.
Upregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis.
Data show that androgen receptor variant AR-V9 (AR-V9) may play a significant role in promoting androgen-independent growth of castration-resistant prostate cancer (CRPC) cells and that AR-V9 mRNA expression in CRPC metastases was predictive of primary resistance to abiraterone acetate.
Within an institutional cohort the RNA ISH assay identified AR-V7 within FFPE tissue and may have prognostic value in metastatic castration-sensitive prostate cancer. These preliminary findings warrant further study in larger cohorts.
AR splice variants both comprising in-frame modifications one being an insertion (69bp insertion into intron 2) and the other a deletion (exon 3) are associated with polycystic ovary syndrome.
The identification of elevated AR mRNA quantitation in hair follicles is a useful tool for identifying potentially abnormal androgen sensitivity in androgenetic alopecia patients.
The presence of long CAG repeat sequence and AR protein expression were in relation to survival of MBC patients. The CAG repeat length and AR expression were two independent prognostic indicators in MBC patients.
Androgen receptor gene regions encoding the hormone binding domain did not contain any missense mutation and were not involved in hepatocarcinogenesis.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.